Skip to main content
Erschienen in: Drugs 5/2008

01.04.2008 | Adis Drug Profile

Dalbavancin

A Viewpoint by Eric S. Schweiger

verfasst von: Eric S. Schweiger

Erschienen in: Drugs | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Excerpt

As the rates of antibiotic resistant bacteria continue to rise, the need for additional antibacterials to add to our armamentarium grows. Dalbavancin is a new medication under review by the US FDA for the treatment of complicated skin and skin structure infections. Dalbavancin, belonging to the same class as vancomycin, is a semi-synthetic glycoprotein that acts by inhibiting bacterial cell wall synthesis. …
Literatur
1.
Zurück zum Zitat Appelbaum PC, Bozdogan B. Vancomycin resistance in Staphylococcus aureus. Clin Lab Med 2004 Jun; 24(2): 381–402PubMedCrossRef Appelbaum PC, Bozdogan B. Vancomycin resistance in Staphylococcus aureus. Clin Lab Med 2004 Jun; 24(2): 381–402PubMedCrossRef
Metadaten
Titel
Dalbavancin
A Viewpoint by Eric S. Schweiger
verfasst von
Eric S. Schweiger
Publikationsdatum
01.04.2008
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868050-00007

Weitere Artikel der Ausgabe 5/2008

Drugs 5/2008 Zur Ausgabe

Adis Drug Profile

Dalbavancin

Adis Drug Evaluation

Lanreotide Autogel®

Therapy in Practice

Rheumatoid Arthritis

Adis Drug Evaluation

Bupropion

Adis Drug Profile

Temsirolimus

Adis Drug Profile

Dalbavancin